Pacira BioSciences, Inc.
NASDAQ:PCRX · NASDAQ Global Select
-$0.18 today
Vol 0.76M · Avg 0.57M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1.0%
avg -1.0%
ROIC
1.2%
avg 0.4%
ROA
0.6%
avg -0.6%
Analysis
ROIC is currently the strongest return metric at 1.2% versus its period average of 0.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Frank D. Lee | Chief Executive Officer & Director | $2.42M | — | 58 | $660,830.84 | 1.68% |
Lauren Bullaro Riker | Principal Accounting Officer & Senior Vice President of Finance | $1.95M | — | 47 | $62,284.24 | 0.16% |
Brendan Teehan | Chief Commercial Officer | $1.16M | — | 57 | $100,934.27 | 0.26% |
Jonathan Slonin | Chief Medical Officer | $1.11M | — | 51 | $218,912.18 | 0.56% |
Kristen Williams | Chief Administrative Officer & Secretary | $1.10M | — | 52 | $167,062.00 | 0.42% |
Shawn Cross | Chief Financial Officer | $1.03M | — | 58 | $150,000.00 | 0.38% |
Anthony Molloy | Chief Legal & Compliance Officer | $581,410.00 | — | 52 | $12,877.00 | 0.03% |
Christopher C. Young | Chief Manufacturing Officer | — | — | 54 | $17,798.00 | 0.05% |
Krys Corbett | Chief Business Officer | — | — | — | — | — |
Susan Mesco | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$2.57M
Net Sentiment
$2.57M
Net selling
Most Active
Cross Shawn
6 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $2.57M over the last 12 months. That adds up to net selling of $2.57M. Cross Shawn was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +38.4% (15yr)1 analysts |
| Revenue | N/A | N/A | +85.4% | +9.2% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | +38.1% (15yr)3 analysts |
| EBIT | N/A | N/A | N/A | +13.1% (15yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +85.4% over three years. Forward estimates point to EPS at +38.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.88B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.58B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.07B
Cronos Group Inc.
NASDAQ:CRON
$991.06M
Xencor, Inc.
NASDAQ:XNCR
$938.88M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$855.87M
Oculis Holding AG
NASDAQ:OCS
$629.04M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$607.61M
Who manages PCRX?
Pacira BioSciences, Inc. (PCRX) lists 10 active executives. The top listed executive is Kristen Williams, Chief Administrative Officer & Secretary.
Are PCRX insiders buying or selling?
Recent insider activity shows net buying of $40.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.